ArticleTransfusion2026
Trends in cryoprecipitate transfusion in the United States.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in cryoprecipitate transfusion in the United States.Transfusion · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNational trends in cryoprecipitate transfusion and patient- and hospital-level factors associated with cryoprecipitate transfusion use among US hospitalizations are not well characterized. STUDY DESIGN AND
methodsThis descriptive study used the National Inpatient Sample (NIS) to estimate overall and sex-specific trends in cryoprecipitate transfusion from 2016 to 2022. Adult hospitalizations (≥18 years) receiving cryoprecipitate were included. The unit of analysis was the hospitalization record, and sampling weights were applied to produce nationally representative estimates. Factors associated with cryoprecipitate transfusion in 2022 were evaluated using multivariable Poisson regression.
resultsBetween 2016 and 2022, there were 205,075,194 weighted hospitalizations, of which 181,950 (0.089%) involved cryoprecipitate transfusion. The prevalence of cryoprecipitate transfusion increased significantly from 0.063% in 2016 to 0.110% in 2022. In multivariable analysis, cryoprecipitate transfusion was more likely among patients aged 60-70 years (vs. 18-30 years; adjusted prevalence ratio [adjPR] = 2.34 [95% confidence intervals (CI) = 2.03-2.70]). Transfusion was also associated with non-White patients, those from higher-income areas, elective admissions (vs. nonelective admissions; adjPR = 1.48 [95% CI = 1.32-1.66]), larger hospital bed size (vs. small; adjPR = 2.71 [95% CI = 2.14-3.43]), and in metropolitan teaching hospitals (vs. nonteaching; adjPR = 3.04 [95% CI = 2.50-3.69]). The prevalence of cryoprecipitate transfusion was lower among females (adjPR = 0.59 [95% CI = 0.55-0.62]), Medicare-covered hospitalizations (vs. Private; adjPR = 0.85 [95% CI = 0.78-0.93]), and admission to private investor-own hospitals (vs. government nonfederal hospitals; adjPR = 0.56 [95% CI = 0.36-0.87]). DISCUSSION: Cryoprecipitate transfusion among US hospitalizations increased from 2016 to 2022, reflecting evolving transfusion practices and the need for continued evaluation of fibrinogen replacement strategies and appropriate cryoprecipitate utilization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.